secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2023-09-15T23:59:59+00:00
Accession:  0001493152-23-032781
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem shareholders approve increase in authorized common shares to 3 billion
-----------------------------------------------------------------------------

- Authorized common shares increased to 3,000,000,000 (from previous amount) effective Sept 15, 2023.
- Saundra Pelletier re-elected as Class III director; advisory say-on-pay approved with 4.75M votes for.
- BPM LLP ratified as independent auditor for FY 2023; all proposals passed with large majorities.
- Meeting quorum: 5,011,486 votes (58.6% of eligible) with common stock holders representing 13%.
- Massive authorized share increase signals potential substantial dilution for existing shareholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223032781/0001493152-23-032781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223032781/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-032781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer